Even with a handful of FDA-approved CAR therapies — largely utilizing a affected person’s personal T cells to go after blood cancers — drastically altering the therapy panorama for a few of the most difficult circumstances, the sphere is now reckoning with the restrictions of the strategy. “One of many caveats of CAR T cell remedy is that it is a residing drug,” stated Daniel Powell, Jr., a most cancers biologist on the College of Pennsylvania. “As soon as it is administered to sufferers, we’ve no means to regulate the exercise.”
Acknowledging that the unique structure might not have been versatile or controllable sufficient for an efficient most cancers therapy, researchers are actually going again to the drafting board to rethink CAR designs and capabilities. A brand new paradigm is the “common CAR,” a deconstructed CAR that researchers can customise to go after a virtually limitless vary of antigens.
In 2023, Jason Lohmueller, an artificial biologist on the College of Pittsburgh developed a brand new option to engineer common CAR: SNAP-CAR (2). These modular CAR present a option to make immunotherapy much less poisonous whereas conserving tempo with quickly evolving cancers. Alongside Coeptis Therapeutics, a biotechnology firm that has licensed the expertise, Lohmueller hopes that bringing this strategy to the clinic will make CAR therapies a more practical possibility for extra sufferers.
A common resolution?
Within the early 2010s, the primary standard CAR-based cell therapies raced towards the clinic. The CAR T cells that achieved early successes in scientific trials for treating blood cancers have been a part of the second technology, whereby engineered cells expressed a cancer-antigen-specific receptor hooked up to a T cell floor protein, alongside a costimulatory molecule corresponding to CD28 or 4-1BB to make the cells much more potent (1). Nonetheless, this strategy wasn’t flawless.
The primary FDA-approved CAR T cell remedy, Kymriah, focused a B cell floor protein referred to as CD19 (3). B cells proliferate wildly in sufferers with cancers corresponding to acute lymphoblastic leukemia, and these CAR T cells used CD19 to search out and kill these cells to regulate the most cancers. But when even just a few cancerous B cells don’t categorical CD19, these cells can evade the CAR T cell remedy and drive most cancers relapse. This course of, referred to as antigen loss or antigen escape, limits the long-term effectiveness of CAR therapies; in CD19 CAR scientific trials, as many as 50 p.c of individuals finally relapsed (4).
Hopefully it may very well be a really customized therapeutic manner down the road. You possibly can display screen a affected person’s tumor, work out what antigens they’ve, and work out what [antibody] adaptors to make use of, all utilizing the identical CAR T cell.
– Jason Lohmueller, College of Pittsburgh
CAR therapies also can have nasty uncomfortable side effects. CD19, for instance, is on the floor of each cancerous and wholesome B cells. When anti-CD19 CAR T cells kill wholesome B cells, sufferers require transfusions of immune molecules to keep up their defenses in opposition to infections. For different organs, it isn’t as straightforward to compensate for killing wholesome cells.
Powell suspected that these limitations of CAR T cells may very well be addressed with a comparatively easy change: uncoupling the inner molecular pathways mediating the immune response from the exterior receptors that acknowledge a most cancers antigen. By separating the useful components of a CAR T cell, physicians may flip it on or off or redirect it towards a brand new antigen by modifying simply its exterior parts.
In 2012, Powell’s group first proposed the thought of common CAR in a paper presenting a modular system based mostly on a pair of molecules, biotin and avidin, that bind to one another (5). The researchers engineered the T cells to specific avidin on their surfaces, hooked up to inside proteins that might set off an immune assault. Additionally they engineered biotin-labeled antibodies that focused an antigen of curiosity. By administering the T cells alongside the antibodies, the antibodies’ biotin tags would bind to the T cell’s avidin molecules to basically reconstruct a useful CAR T cell with extra flexibility to find out its goal.
Powell hoped that this is able to assist keep away from antigen escape. Somewhat than simply concentrating on CD19, the researchers may administer antibodies that bind a number of leukemia antigens in order that the CAR T cells have a number of methods to determine and kill most cancers cells.
“You are responding to the evolution of the most cancers by creating further brokers that help you goal new antigens,” he stated. “That is in all probability the only largest profit.”
Higher constructing blocks
Lohmueller heard about Powell’s common CAR when he was a graduate pupil at Harvard College, and he was intrigued by its potential. “That is a lot better than the choice of creating two completely different CAR T cell merchandise that acknowledge completely different antigens as a result of it is double the work,” he stated. “[With this] unbelievable expertise, you possibly can have plug-and-play concentrating on of CAR T cells.”
When he tried to make use of current common CAR approaches to develop CAR T cells concentrating on mucin 1 (MUC1), an antigen discovered on many sorts of most cancers, it wasn’t as efficient as he had hoped. He turned his consideration to designing stronger common CAR. This required growing the affinity between the T cell and the antibody. At first, he simply tried tweaking avidin and biotin to make them bind extra tightly, however he realized that the CAR exercise would all the time be restricted by intermittent binding of avidin and biotin (6).

Jason Lohmueller developed the SNAP-CAR system to make stronger common CAR T cells.
Credit score: Aimee Obidzinski/College of Pittsburgh
To maximise exercise, he wanted to completely connect the antibody to the T cell with a covalent bond — one thing that Powell’s group had additionally begun to incorporate into their common CAR (7). “It mimics the pure conventional CAR [fusion proteins] in being hooked up,” he stated. “By utilizing that covalent bond, we will obtain extra conventional CAR-like exercise with a common system.”
To perform this, his group used the SNAP-tag system that had been beforehand developed to make fusion proteins held collectively by a covalent bond (8). SNAP is a self-labeling enzyme. When it sees its goal molecule, benzylguanine, it attaches itself to the goal. SNAP may take the place of avidin within the recipe for common CAR, and benzylguanine may change biotin. When benzylguanine-tagged antibodies encountered SNAP on a T cell’s floor, they covalently hooked up to the T cell to kind a useful CAR that might acknowledge a goal antigen and set off the T cell to launch cell-killing molecules.
In a 2023 examine, Lohmueller’s group discovered that SNAP-CAR T cells may efficiently struggle a tumor in a mouse mannequin (2). Importantly, nonetheless, SNAP-CAR additionally supplied a path to tuning the efficiency of the remedy by growing or lowering the degrees of the antigen-targeting antibody. “If we titrate the quantity of [antibody] adaptor, we will get completely different ranges of tumor cell killing,” Lohmueller stated. “It is very nice to have that additional management.”
Lohmueller additionally famous that the SNAP-CAR system accommodates a number of antibodies to focus on a wider vary of antigens. The restrict of what number of antibodies can be utilized for one affected person remains to be unknown. Nonetheless, he proposed that these antibodies may very well be administered all of sudden to focus on a number of antigens concurrently or in sequence, relying on how the most cancers evolves throughout therapy. In spite of everything, the antibody constructing blocks of those CAR T cells are dynamic. After being infused into the affected person, they float round for weeks on common, and even the antibodies that bind to the T cells solely stay lively there for just a few days. This provides physicians the chance to repeatedly replace the combination of antibodies accessible to kind CAR T cells within the affected person.
“It may very well be a really customized therapeutic manner down the road,” Lohmueller stated. “You possibly can display screen a affected person’s tumor, work out what antigens they’ve, and work out what [antibody] adaptors to make use of, all utilizing the identical CAR T cell.”
New frontiers for SNAP
Even earlier than the examine was printed, Lohmueller’s SNAP-CAR expertise attracted Coeptis Therapeutics’ consideration. In 2022, the corporate, which focuses on creating cell therapies, entered into an settlement with the College of Pittsburgh to license the expertise for the event of SNAP-CAR therapeutics. “There is a clear attraction to therapies that may very well be broadly relevant,” stated Colleen Delaney, chief scientific and medical officer of Coeptis Therapeutics and an oncologist on the College of Washington.

SNAP-CAR may result in an off-the-shelf common CAR T cell remedy.
Credit score: Coeptis Therapeutics
Particularly, Coeptis Therapeutics is keen on making off-the-shelf allogeneic SNAP-CAR therapies that can be utilized for any affected person. Usually, cells are extracted from a affected person, engineered to specific the CAR, and infused again into the affected person to keep away from immune rejection of cells from a special donor. However this autologous strategy is time-consuming and costly. An allogeneic remedy may very well be manufactured in bulk upfront and distributed to hospitals or pharmacies for a lot of completely different sufferers to make use of. “The remedy is actually ready for a affected person versus a affected person ready for the remedy,” Delaney stated.
SNAP-CAR add one other dimension to the flexibleness of an allogeneic remedy: Now, one remedy can be utilized for a lot of sufferers with many ailments, as nicely, for the reason that CAR wouldn’t have a pre-defined goal.
There are nonetheless many hurdles to creating allogeneic T cell therapies as a result of T cells have receptors that may set off graft-versus-host illness (GVHD) when infused into a special individual (9). Whereas Lohmueller’s group continues to engineer T cells, Coeptis Therapeutics focuses on a special sort of immune cell: pure killer (NK) cells. These cells are simpler to transplant from one individual into one other with out triggering GVHD. Part 1/2 scientific trials have already proven that CAR NK cells can goal most cancers with minimal uncomfortable side effects, and SNAP-CAR may make these therapies much more versatile, Delaney stated (10).
“Sooner or later, you can create grasp a number of NK cells which are expressing common CAR and make the most of them to deal with tens or a whole lot of sufferers,” Powell stated.

Delaney, who’s a transplant doctor, believes that potential makes use of for SNAP-CAR transcend most cancers therapy.
Credit score: Coeptis Therapeutics
Coeptis Therapeutics is at present optimizing SNAP CAR for NK cells. They begin with stem cells that the researchers differentiate into NK cells, a course of that’s modeled after an allogeneic cell remedy platform that Delaney beforehand developed on the College of Washington.
The group is testing lentivirus and retrovirus vectors to ship the DNA encoding the SNAP protein and its inside parts into the cells. However viral vectors could be an costly and scarce sources. To scale back the quantity and the price of virus required, Coeptis Therapeutics is transfecting the stem cells early of their differentiation part when the variety of cells remains to be low. They’ve discovered that the SNAP-CAR proteins persist within the NK cells as they differentiate, permitting them to create batches of allogeneic SNAP-CAR NK cells that may be repeatedly infused into sufferers alongside antibodies to level the cells at their targets.
As soon as they optimize the system and take a look at it in animal fashions of leukemia and stable tumors, the Coeptis Therapeutics group hopes to use for Investigational New Drug standing throughout the subsequent 24 months. Delaney thinks Coeptis Therapeutics’ strategy will stand out in a crowded area of CAR therapies. “Lots of people are doing this, so what I hope to get throughout is that we will do that in a extra efficacious manner,” Delaney stated.
From bench to bedside
For SNAP-CAR cell therapies to make it to the clinic, researchers should present that they will work at the least in addition to standard CAR. Lohmueller stated that the information already present that, and now he hopes to display that SNAP-CAR can do much more. For instance, standard CAR can have off-target results that result in toxicity, however Lohmueller lately confirmed that it’s potential to design the covalent hyperlink between the antibody and SNAP protein in order that it may be severed by an “off swap,” corresponding to UV gentle or a small molecule (11).
The remedy is actually ready for a affected person versus a affected person ready for the remedy.
– Colleen Delaney, Coeptis Therapeutics
Equally, the researchers can construct in “on-switches,” for instance, in order that the antibody solely binds to the SNAP protein within the low-oxygen circumstances present in a tumor. “We are able to do all types of cool chemistry to make that chemical tag accessible for binding,” Lohmueller stated. Although allogeneic T cell merchandise are tougher to develop, he nonetheless believes that will be the perfect remaining product, not just for most cancers therapy. “You possibly can have it able to go to tailor to no matter illness you may have,” Lohmueller stated.
Coeptis Therapeutics licensed the SNAP CAR expertise for autoimmune indications as nicely. For instance, in lupus nephritis, the place B cells assault the affected person’s personal cells, researchers examined whether or not CAR that may goal CD19 may provide a brand new therapy avenue. In accordance with Delaney, SNAP CAR may increase these therapies and would possibly even assist deal with infectious ailments in immunocompromised folks.
That is an space the place Delaney has seen the necessity firsthand as a practising doctor, a task she nonetheless holds. “It helps me preserve an understanding of what the unmet want is for these sufferers,” she stated. “My hope is to make these therapies extra clinically accessible.”
References
- Mitra, A. et al. From bench to bedside: the historical past and progress of CAR T cell remedy. Entrance Immunol 14, 1188049 (2023).
- Ruffo, E. et al. Publish-translational covalent meeting of CAR and synNotch receptors for programmable antigen concentrating on. Nat Commun 14, 2463 (2023).
- Maude, S.L. et al. Tisagenlecleucel in Kids and Younger Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 378, 439-448 (2018).
- Majzner, R.G. et al. Tumor Antigen Escape from CAR T-cell Remedy. Most cancers Discov 8, 1219-1226 (2018).
- Urbanska, Okay. et al. A common technique for adoptive immunotherapy of most cancers via use of a novel T-cell antigen receptor. Most cancers Res 72, 1844-52 (2012).
- Lohmueller, J.J. et al. mSA2 affinity-enhanced biotin-binding CAR T cells for common tumor concentrating on. Oncoimmunology 7, e1368604 (2018).
- Minutolo, N.G. et al. Quantitative Management of Gene-Engineered T-Cell Exercise via the Covalent Attachment of Focusing on Ligands to a Common Immune Receptor. J Am Chem Soc 142, 6554-6568 (2020).
- Keppler, A. et al. A common technique for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 21, 86-9 (2003).
- Basar, R. et al. Subsequent-generation cell therapies: the rising function of CAR-NK cells. Blood Adv 4, 5868-5876 (2020).
- Marin, D. et al. Security, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a part 1/2 trial. Nat Med 30, 772-784 (2024).
- Kvorjak, M. et al. Conditional Management of Common CAR T Cells by Cleavable OFF-Swap Adaptors. ACS Synth Biol 12, 2996-3007 (2023).
“,”readingTimeEstimate”:10,”aImg”:{“assetNo”:41633,”identify”:”untitled-design-2024-07-16t170840-782-1″,”description”:”Avani Parikh wears a lab coat whereas conducting an experiment at a lab bench.”,”standing”:”prepared”,”sort”:”aImg”,”createdDate”:”2024-07-16 21:14:34″,”lastUpdated”:”2024-07-16 21:14:45″,”caption”:”Avani Parikh, a graduate pupil within the Lohmueller group, helped take a look at SNAP-CAR T cells’ cancer-killing skills.”,”reference”:”Credit score: Jason Lohmueller”,”recordsdata”:[{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.png”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.png”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.png”,”createdDate”:”2024-07-16 21:14:41″,”lastUpdated”:”2024-07-16 21:14:41″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.png”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.png”,”createdDate”:”2024-07-16 21:14:43″,”lastUpdated”:”2024-07-16 21:14:43″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.png”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.png”,”createdDate”:”2024-07-16 21:14:45″,”lastUpdated”:”2024-07-16 21:14:45″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1.png”,”createdDate”:”2024-07-16 21:14:35″,”lastUpdated”:”2024-07-16 21:14:35″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.webp”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.webp”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.webp”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.webp”,”createdDate”:”2024-07-16 21:14:42″,”lastUpdated”:”2024-07-16 21:14:42″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.webp”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.webp”,”createdDate”:”2024-07-16 21:14:44″,”lastUpdated”:”2024-07-16 21:14:44″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.webp”,”createdDate”:”2024-07-16 21:14:39″,”lastUpdated”:”2024-07-16 21:14:39″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”}]},”hImg”:null,”articleImageStructuredData”:””picture” : {n “@sort”: “ImageObject”,n “peak”: “220”,n “width”: “220”,n “url”: “https://cdn.drugdiscoverynews.com/property/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.png”n },”,”hasAssets”:true,”eventDate”:{},”hasEvent”:false,”pastEvent”:false,”isSponsored”:false,”isProminent”:false,”publishedDateText”:”Jul 17, 2024″,”fullSlug”:”/car-t-cells-in-a-snap-15995″,”cleanURL”:”car-t-cells-in-a-snap-15995″,”absoluteURL”:”https://www.drugdiscoverynews.com/car-t-cells-in-a-snap-15995″,”tagCleanUrlList”:”car-t,car-t-cell-therapy,most cancers,cell-therapy,immunotherapy,security,nk-cells,protein,allogeneic”,”sortedaImages”:{“sizeSrcSets”:{“M”:[{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.webp”,”createdDate”:”2024-07-16 21:14:39″,”lastUpdated”:”2024-07-16 21:14:39″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.png”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”S”:[{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.webp”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.png”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”L”:[{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.webp”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.png”,”createdDate”:”2024-07-16 21:14:41″,”lastUpdated”:”2024-07-16 21:14:41″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”TL”:[{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.webp”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.png”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”X”:[{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.webp”,”createdDate”:”2024-07-16 21:14:42″,”lastUpdated”:”2024-07-16 21:14:42″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.png”,”createdDate”:”2024-07-16 21:14:43″,”lastUpdated”:”2024-07-16 21:14:43″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”T”:[{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.webp”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.png”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”O”:[{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.webp”,”createdDate”:”2024-07-16 21:14:44″,”lastUpdated”:”2024-07-16 21:14:44″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.png”,”createdDate”:”2024-07-16 21:14:45″,”lastUpdated”:”2024-07-16 21:14:45″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1.png”,”createdDate”:”2024-07-16 21:14:35″,”lastUpdated”:”2024-07-16 21:14:35″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}]},”altTag”:”Avani Parikh wears a lab coat whereas conducting an experiment at a lab bench.”},”isWebinar”:false,”isDefault”:false,”isFeatured”:true,”isHero”:false,”isHeader”:true,”isConversion”:false,”wordCount”:2705,”adsTargetValue”:[7,2,9],”attachedArticles”:null,”sponsoredVendorNos”:[],”sponsorNames”:[],”originalSponsorships”:[],”singleAuthorAsset”:{“sizeSrcSets”:{“M”:[{“assetNo”:39024,”size”:”M”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-m.webp”,”createdDate”:”2022-04-06 19:06:57″,”lastUpdated”:”2022-04-06 19:06:57″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”M”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-m.png”,”createdDate”:”2022-04-06 19:06:58″,”lastUpdated”:”2022-04-06 19:06:58″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”O”:[{“assetNo”:39024,”size”:”O”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-o.webp”,”createdDate”:”2022-04-06 19:07:01″,”lastUpdated”:”2022-04-06 19:07:01″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”O”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-o.png”,”createdDate”:”2022-04-06 19:07:02″,”lastUpdated”:”2022-04-06 19:07:02″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:39024,”size”:”O”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan.png”,”createdDate”:”2022-04-06 19:06:55″,”lastUpdated”:”2022-04-06 19:06:55″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”L”:[{“assetNo”:39024,”size”:”L”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-l.webp”,”createdDate”:”2022-04-06 19:06:58″,”lastUpdated”:”2022-04-06 19:06:58″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”L”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-l.png”,”createdDate”:”2022-04-06 19:06:59″,”lastUpdated”:”2022-04-06 19:06:59″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”X”:[{“assetNo”:39024,”size”:”X”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-x.webp”,”createdDate”:”2022-04-06 19:07:00″,”lastUpdated”:”2022-04-06 19:07:00″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”X”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-x.png”,”createdDate”:”2022-04-06 19:07:01″,”lastUpdated”:”2022-04-06 19:07:01″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”S”:[{“assetNo”:39024,”size”:”S”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-s.webp”,”createdDate”:”2022-04-06 19:06:56″,”lastUpdated”:”2022-04-06 19:06:56″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”S”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-s.png”,”createdDate”:”2022-04-06 19:06:57″,”lastUpdated”:”2022-04-06 19:06:57″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”T”:[{“assetNo”:39024,”size”:”T”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-t.webp”,”createdDate”:”2022-04-06 19:06:56″,”lastUpdated”:”2022-04-06 19:06:56″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”T”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-t.png”,”createdDate”:”2022-04-06 19:06:56″,”lastUpdated”:”2022-04-06 19:06:56″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}]},”altTag”:”Aparna Nathan Headshot”},”showAttachedArticles”:true,”disableAutoAttachedArticles”:false}” data-order=”first”>
Even with a handful of FDA-approved CAR therapies — largely utilizing a affected person’s personal T cells to go after blood cancers — drastically altering the therapy panorama for a few of the most difficult circumstances, the sphere is now reckoning with the restrictions of the strategy. “One of many caveats of CAR T cell remedy is that it is a residing drug,” stated Daniel Powell, Jr., a most cancers biologist on the College of Pennsylvania. “As soon as it is administered to sufferers, we’ve no means to regulate the exercise.”
Acknowledging that the unique structure might not have been versatile or controllable sufficient for an efficient most cancers therapy, researchers are actually going again to the drafting board to rethink CAR designs and capabilities. A brand new paradigm is the “common CAR,” a deconstructed CAR that researchers can customise to go after a virtually limitless vary of antigens.
In 2023, Jason Lohmueller, an artificial biologist on the College of Pittsburgh developed a brand new option to engineer common CAR: SNAP-CAR (2). These modular CAR present a option to make immunotherapy much less poisonous whereas conserving tempo with quickly evolving cancers. Alongside Coeptis Therapeutics, a biotechnology firm that has licensed the expertise, Lohmueller hopes that bringing this strategy to the clinic will make CAR therapies a more practical possibility for extra sufferers.
A common resolution?
Within the early 2010s, the primary standard CAR-based cell therapies raced towards the clinic. The CAR T cells that achieved early successes in scientific trials for treating blood cancers have been a part of the second technology, whereby engineered cells expressed a cancer-antigen-specific receptor hooked up to a T cell floor protein, alongside a costimulatory molecule corresponding to CD28 or 4-1BB to make the cells much more potent (1). Nonetheless, this strategy wasn’t flawless.
The primary FDA-approved CAR T cell remedy, Kymriah, focused a B cell floor protein referred to as CD19 (3). B cells proliferate wildly in sufferers with cancers corresponding to acute lymphoblastic leukemia, and these CAR T cells used CD19 to search out and kill these cells to regulate the most cancers. But when even just a few cancerous B cells don’t categorical CD19, these cells can evade the CAR T cell remedy and drive most cancers relapse. This course of, referred to as antigen loss or antigen escape, limits the long-term effectiveness of CAR therapies; in CD19 CAR scientific trials, as many as 50 p.c of individuals finally relapsed (4).
Hopefully it may very well be a really customized therapeutic manner down the road. You possibly can display screen a affected person’s tumor, work out what antigens they’ve, and work out what [antibody] adaptors to make use of, all utilizing the identical CAR T cell.
– Jason Lohmueller, College of Pittsburgh
CAR therapies also can have nasty uncomfortable side effects. CD19, for instance, is on the floor of each cancerous and wholesome B cells. When anti-CD19 CAR T cells kill wholesome B cells, sufferers require transfusions of immune molecules to keep up their defenses in opposition to infections. For different organs, it isn’t as straightforward to compensate for killing wholesome cells.
Powell suspected that these limitations of CAR T cells may very well be addressed with a comparatively easy change: uncoupling the inner molecular pathways mediating the immune response from the exterior receptors that acknowledge a most cancers antigen. By separating the useful components of a CAR T cell, physicians may flip it on or off or redirect it towards a brand new antigen by modifying simply its exterior parts.
In 2012, Powell’s group first proposed the thought of common CAR in a paper presenting a modular system based mostly on a pair of molecules, biotin and avidin, that bind to one another (5). The researchers engineered the T cells to specific avidin on their surfaces, hooked up to inside proteins that might set off an immune assault. Additionally they engineered biotin-labeled antibodies that focused an antigen of curiosity. By administering the T cells alongside the antibodies, the antibodies’ biotin tags would bind to the T cell’s avidin molecules to basically reconstruct a useful CAR T cell with extra flexibility to find out its goal.
Powell hoped that this is able to assist keep away from antigen escape. Somewhat than simply concentrating on CD19, the researchers may administer antibodies that bind a number of leukemia antigens in order that the CAR T cells have a number of methods to determine and kill most cancers cells.
“You are responding to the evolution of the most cancers by creating further brokers that help you goal new antigens,” he stated. “That is in all probability the only largest profit.”
Higher constructing blocks
Lohmueller heard about Powell’s common CAR when he was a graduate pupil at Harvard College, and he was intrigued by its potential. “That is a lot better than the choice of creating two completely different CAR T cell merchandise that acknowledge completely different antigens as a result of it is double the work,” he stated. “[With this] unbelievable expertise, you possibly can have plug-and-play concentrating on of CAR T cells.”
When he tried to make use of current common CAR approaches to develop CAR T cells concentrating on mucin 1 (MUC1), an antigen discovered on many sorts of most cancers, it wasn’t as efficient as he had hoped. He turned his consideration to designing stronger common CAR. This required growing the affinity between the T cell and the antibody. At first, he simply tried tweaking avidin and biotin to make them bind extra tightly, however he realized that the CAR exercise would all the time be restricted by intermittent binding of avidin and biotin (6).

Jason Lohmueller developed the SNAP-CAR system to make stronger common CAR T cells.
Credit score: Aimee Obidzinski/College of Pittsburgh
To maximise exercise, he wanted to completely connect the antibody to the T cell with a covalent bond — one thing that Powell’s group had additionally begun to incorporate into their common CAR (7). “It mimics the pure conventional CAR [fusion proteins] in being hooked up,” he stated. “By utilizing that covalent bond, we will obtain extra conventional CAR-like exercise with a common system.”
To perform this, his group used the SNAP-tag system that had been beforehand developed to make fusion proteins held collectively by a covalent bond (8). SNAP is a self-labeling enzyme. When it sees its goal molecule, benzylguanine, it attaches itself to the goal. SNAP may take the place of avidin within the recipe for common CAR, and benzylguanine may change biotin. When benzylguanine-tagged antibodies encountered SNAP on a T cell’s floor, they covalently hooked up to the T cell to kind a useful CAR that might acknowledge a goal antigen and set off the T cell to launch cell-killing molecules.
In a 2023 examine, Lohmueller’s group discovered that SNAP-CAR T cells may efficiently struggle a tumor in a mouse mannequin (2). Importantly, nonetheless, SNAP-CAR additionally supplied a path to tuning the efficiency of the remedy by growing or lowering the degrees of the antigen-targeting antibody. “If we titrate the quantity of [antibody] adaptor, we will get completely different ranges of tumor cell killing,” Lohmueller stated. “It is very nice to have that additional management.”
Lohmueller additionally famous that the SNAP-CAR system accommodates a number of antibodies to focus on a wider vary of antigens. The restrict of what number of antibodies can be utilized for one affected person remains to be unknown. Nonetheless, he proposed that these antibodies may very well be administered all of sudden to focus on a number of antigens concurrently or in sequence, relying on how the most cancers evolves throughout therapy. In spite of everything, the antibody constructing blocks of those CAR T cells are dynamic. After being infused into the affected person, they float round for weeks on common, and even the antibodies that bind to the T cells solely stay lively there for just a few days. This provides physicians the chance to repeatedly replace the combination of antibodies accessible to kind CAR T cells within the affected person.
“It may very well be a really customized therapeutic manner down the road,” Lohmueller stated. “You possibly can display screen a affected person’s tumor, work out what antigens they’ve, and work out what [antibody] adaptors to make use of, all utilizing the identical CAR T cell.”
New frontiers for SNAP
Even earlier than the examine was printed, Lohmueller’s SNAP-CAR expertise attracted Coeptis Therapeutics’ consideration. In 2022, the corporate, which focuses on creating cell therapies, entered into an settlement with the College of Pittsburgh to license the expertise for the event of SNAP-CAR therapeutics. “There is a clear attraction to therapies that may very well be broadly relevant,” stated Colleen Delaney, chief scientific and medical officer of Coeptis Therapeutics and an oncologist on the College of Washington.

SNAP-CAR may result in an off-the-shelf common CAR T cell remedy.
Credit score: Coeptis Therapeutics
Particularly, Coeptis Therapeutics is keen on making off-the-shelf allogeneic SNAP-CAR therapies that can be utilized for any affected person. Usually, cells are extracted from a affected person, engineered to specific the CAR, and infused again into the affected person to keep away from immune rejection of cells from a special donor. However this autologous strategy is time-consuming and costly. An allogeneic remedy may very well be manufactured in bulk upfront and distributed to hospitals or pharmacies for a lot of completely different sufferers to make use of. “The remedy is actually ready for a affected person versus a affected person ready for the remedy,” Delaney stated.
SNAP-CAR add one other dimension to the flexibleness of an allogeneic remedy: Now, one remedy can be utilized for a lot of sufferers with many ailments, as nicely, for the reason that CAR wouldn’t have a pre-defined goal.
There are nonetheless many hurdles to creating allogeneic T cell therapies as a result of T cells have receptors that may set off graft-versus-host illness (GVHD) when infused into a special individual (9). Whereas Lohmueller’s group continues to engineer T cells, Coeptis Therapeutics focuses on a special sort of immune cell: pure killer (NK) cells. These cells are simpler to transplant from one individual into one other with out triggering GVHD. Part 1/2 scientific trials have already proven that CAR NK cells can goal most cancers with minimal uncomfortable side effects, and SNAP-CAR may make these therapies much more versatile, Delaney stated (10).
“Sooner or later, you can create grasp a number of NK cells which are expressing common CAR and make the most of them to deal with tens or a whole lot of sufferers,” Powell stated.

Delaney, who’s a transplant doctor, believes that potential makes use of for SNAP-CAR transcend most cancers therapy.
Credit score: Coeptis Therapeutics
Coeptis Therapeutics is at present optimizing SNAP CAR for NK cells. They begin with stem cells that the researchers differentiate into NK cells, a course of that’s modeled after an allogeneic cell remedy platform that Delaney beforehand developed on the College of Washington.
The group is testing lentivirus and retrovirus vectors to ship the DNA encoding the SNAP protein and its inside parts into the cells. However viral vectors could be an costly and scarce sources. To scale back the quantity and the price of virus required, Coeptis Therapeutics is transfecting the stem cells early of their differentiation part when the variety of cells remains to be low. They’ve discovered that the SNAP-CAR proteins persist within the NK cells as they differentiate, permitting them to create batches of allogeneic SNAP-CAR NK cells that may be repeatedly infused into sufferers alongside antibodies to level the cells at their targets.
As soon as they optimize the system and take a look at it in animal fashions of leukemia and stable tumors, the Coeptis Therapeutics group hopes to use for Investigational New Drug standing throughout the subsequent 24 months. Delaney thinks Coeptis Therapeutics’ strategy will stand out in a crowded area of CAR therapies. “Lots of people are doing this, so what I hope to get throughout is that we will do that in a extra efficacious manner,” Delaney stated.
From bench to bedside
For SNAP-CAR cell therapies to make it to the clinic, researchers should present that they will work at the least in addition to standard CAR. Lohmueller stated that the information already present that, and now he hopes to display that SNAP-CAR can do much more. For instance, standard CAR can have off-target results that result in toxicity, however Lohmueller lately confirmed that it’s potential to design the covalent hyperlink between the antibody and SNAP protein in order that it may be severed by an “off swap,” corresponding to UV gentle or a small molecule (11).
The remedy is actually ready for a affected person versus a affected person ready for the remedy.
– Colleen Delaney, Coeptis Therapeutics
Equally, the researchers can construct in “on-switches,” for instance, in order that the antibody solely binds to the SNAP protein within the low-oxygen circumstances present in a tumor. “We are able to do all types of cool chemistry to make that chemical tag accessible for binding,” Lohmueller stated. Although allogeneic T cell merchandise are tougher to develop, he nonetheless believes that will be the perfect remaining product, not just for most cancers therapy. “You possibly can have it able to go to tailor to no matter illness you may have,” Lohmueller stated.
Coeptis Therapeutics licensed the SNAP CAR expertise for autoimmune indications as nicely. For instance, in lupus nephritis, the place B cells assault the affected person’s personal cells, researchers examined whether or not CAR that may goal CD19 may provide a brand new therapy avenue. In accordance with Delaney, SNAP CAR may increase these therapies and would possibly even assist deal with infectious ailments in immunocompromised folks.
That is an space the place Delaney has seen the necessity firsthand as a practising doctor, a task she nonetheless holds. “It helps me preserve an understanding of what the unmet want is for these sufferers,” she stated. “My hope is to make these therapies extra clinically accessible.”
References
- Mitra, A. et al. From bench to bedside: the historical past and progress of CAR T cell remedy. Entrance Immunol 14, 1188049 (2023).
- Ruffo, E. et al. Publish-translational covalent meeting of CAR and synNotch receptors for programmable antigen concentrating on. Nat Commun 14, 2463 (2023).
- Maude, S.L. et al. Tisagenlecleucel in Kids and Younger Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 378, 439-448 (2018).
- Majzner, R.G. et al. Tumor Antigen Escape from CAR T-cell Remedy. Most cancers Discov 8, 1219-1226 (2018).
- Urbanska, Okay. et al. A common technique for adoptive immunotherapy of most cancers via use of a novel T-cell antigen receptor. Most cancers Res 72, 1844-52 (2012).
- Lohmueller, J.J. et al. mSA2 affinity-enhanced biotin-binding CAR T cells for common tumor concentrating on. Oncoimmunology 7, e1368604 (2018).
- Minutolo, N.G. et al. Quantitative Management of Gene-Engineered T-Cell Exercise via the Covalent Attachment of Focusing on Ligands to a Common Immune Receptor. J Am Chem Soc 142, 6554-6568 (2020).
- Keppler, A. et al. A common technique for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 21, 86-9 (2003).
- Basar, R. et al. Subsequent-generation cell therapies: the rising function of CAR-NK cells. Blood Adv 4, 5868-5876 (2020).
- Marin, D. et al. Security, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a part 1/2 trial. Nat Med 30, 772-784 (2024).
- Kvorjak, M. et al. Conditional Management of Common CAR T Cells by Cleavable OFF-Swap Adaptors. ACS Synth Biol 12, 2996-3007 (2023).
“,”readingTimeEstimate”:10,”aImg”:{“assetNo”:41633,”identify”:”untitled-design-2024-07-16t170840-782-1″,”description”:”Avani Parikh wears a lab coat whereas conducting an experiment at a lab bench.”,”standing”:”prepared”,”sort”:”aImg”,”createdDate”:”2024-07-16 21:14:34″,”lastUpdated”:”2024-07-16 21:14:45″,”caption”:”Avani Parikh, a graduate pupil within the Lohmueller group, helped take a look at SNAP-CAR T cells’ cancer-killing skills.”,”reference”:”Credit score: Jason Lohmueller”,”recordsdata”:[{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.png”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.png”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.png”,”createdDate”:”2024-07-16 21:14:41″,”lastUpdated”:”2024-07-16 21:14:41″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.png”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.png”,”createdDate”:”2024-07-16 21:14:43″,”lastUpdated”:”2024-07-16 21:14:43″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.png”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.png”,”createdDate”:”2024-07-16 21:14:45″,”lastUpdated”:”2024-07-16 21:14:45″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1.png”,”createdDate”:”2024-07-16 21:14:35″,”lastUpdated”:”2024-07-16 21:14:35″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.webp”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.webp”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.webp”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.webp”,”createdDate”:”2024-07-16 21:14:42″,”lastUpdated”:”2024-07-16 21:14:42″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.webp”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.webp”,”createdDate”:”2024-07-16 21:14:44″,”lastUpdated”:”2024-07-16 21:14:44″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.webp”,”createdDate”:”2024-07-16 21:14:39″,”lastUpdated”:”2024-07-16 21:14:39″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”}]},”hImg”:null,”articleImageStructuredData”:””picture” : {n “@sort”: “ImageObject”,n “peak”: “220”,n “width”: “220”,n “url”: “https://cdn.drugdiscoverynews.com/property/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.png”n },”,”hasAssets”:true,”eventDate”:{},”hasEvent”:false,”pastEvent”:false,”isSponsored”:false,”isProminent”:false,”publishedDateText”:”Jul 17, 2024″,”fullSlug”:”/car-t-cells-in-a-snap-15995″,”cleanURL”:”car-t-cells-in-a-snap-15995″,”absoluteURL”:”https://www.drugdiscoverynews.com/car-t-cells-in-a-snap-15995″,”tagCleanUrlList”:”car-t,car-t-cell-therapy,most cancers,cell-therapy,immunotherapy,security,nk-cells,protein,allogeneic”,”sortedaImages”:{“sizeSrcSets”:{“M”:[{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.webp”,”createdDate”:”2024-07-16 21:14:39″,”lastUpdated”:”2024-07-16 21:14:39″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”M”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-m.png”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”S”:[{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.webp”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”S”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-s.png”,”createdDate”:”2024-07-16 21:14:38″,”lastUpdated”:”2024-07-16 21:14:38″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”L”:[{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.webp”,”createdDate”:”2024-07-16 21:14:40″,”lastUpdated”:”2024-07-16 21:14:40″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”L”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-l.png”,”createdDate”:”2024-07-16 21:14:41″,”lastUpdated”:”2024-07-16 21:14:41″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”TL”:[{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.webp”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”TL”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-tl.png”,”createdDate”:”2024-07-16 21:14:37″,”lastUpdated”:”2024-07-16 21:14:37″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”X”:[{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.webp”,”createdDate”:”2024-07-16 21:14:42″,”lastUpdated”:”2024-07-16 21:14:42″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”X”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-x.png”,”createdDate”:”2024-07-16 21:14:43″,”lastUpdated”:”2024-07-16 21:14:43″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”T”:[{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.webp”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”T”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-t.png”,”createdDate”:”2024-07-16 21:14:36″,”lastUpdated”:”2024-07-16 21:14:36″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”O”:[{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.webp”,”createdDate”:”2024-07-16 21:14:44″,”lastUpdated”:”2024-07-16 21:14:44″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1-o.png”,”createdDate”:”2024-07-16 21:14:45″,”lastUpdated”:”2024-07-16 21:14:45″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:41633,”size”:”O”,”path”:”assets/articleNo/15995/aImg/41633/untitled-design-2024-07-16t170840-782-1.png”,”createdDate”:”2024-07-16 21:14:35″,”lastUpdated”:”2024-07-16 21:14:35″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}]},”altTag”:”Avani Parikh wears a lab coat whereas conducting an experiment at a lab bench.”},”isWebinar”:false,”isDefault”:false,”isFeatured”:true,”isHero”:false,”isHeader”:true,”isConversion”:false,”wordCount”:2705,”adsTargetValue”:[7,2,9],”attachedArticles”:null,”sponsoredVendorNos”:[],”sponsorNames”:[],”originalSponsorships”:[],”singleAuthorAsset”:{“sizeSrcSets”:{“M”:[{“assetNo”:39024,”size”:”M”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-m.webp”,”createdDate”:”2022-04-06 19:06:57″,”lastUpdated”:”2022-04-06 19:06:57″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”M”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-m.png”,”createdDate”:”2022-04-06 19:06:58″,”lastUpdated”:”2022-04-06 19:06:58″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”O”:[{“assetNo”:39024,”size”:”O”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-o.webp”,”createdDate”:”2022-04-06 19:07:01″,”lastUpdated”:”2022-04-06 19:07:01″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”O”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-o.png”,”createdDate”:”2022-04-06 19:07:02″,”lastUpdated”:”2022-04-06 19:07:02″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”},{“assetNo”:39024,”size”:”O”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan.png”,”createdDate”:”2022-04-06 19:06:55″,”lastUpdated”:”2022-04-06 19:06:55″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”L”:[{“assetNo”:39024,”size”:”L”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-l.webp”,”createdDate”:”2022-04-06 19:06:58″,”lastUpdated”:”2022-04-06 19:06:58″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”L”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-l.png”,”createdDate”:”2022-04-06 19:06:59″,”lastUpdated”:”2022-04-06 19:06:59″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”X”:[{“assetNo”:39024,”size”:”X”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-x.webp”,”createdDate”:”2022-04-06 19:07:00″,”lastUpdated”:”2022-04-06 19:07:00″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”X”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-x.png”,”createdDate”:”2022-04-06 19:07:01″,”lastUpdated”:”2022-04-06 19:07:01″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”S”:[{“assetNo”:39024,”size”:”S”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-s.webp”,”createdDate”:”2022-04-06 19:06:56″,”lastUpdated”:”2022-04-06 19:06:56″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”S”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-s.png”,”createdDate”:”2022-04-06 19:06:57″,”lastUpdated”:”2022-04-06 19:06:57″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}],”T”:[{“assetNo”:39024,”size”:”T”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-t.webp”,”createdDate”:”2022-04-06 19:06:56″,”lastUpdated”:”2022-04-06 19:06:56″,”isDeleted”:false,”format”:”webp”,”ext”:”webp”,”type”:”image/webp”},{“assetNo”:39024,”size”:”T”,”path”:”assets/authorNo/343/iImg/39024/aparna-nathan-t.png”,”createdDate”:”2022-04-06 19:06:56″,”lastUpdated”:”2022-04-06 19:06:56″,”isDeleted”:false,”format”:”png”,”ext”:”png”,”type”:”image/png”}]},”altTag”:”Aparna Nathan Headshot”},”showAttachedArticles”:true,”disableAutoAttachedArticles”:false}” data-order=”second”>




